Journal Article

DKFZ-2026-01209

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Chromosome 5q deletion drives evolution of aneuploidy in myeloid neoplasms with complex karyotype.

Creamer, J. P. ; Ray, S. ; Stewart, S. ; Gulsuner, S. ; Saliba, A. N. ; Wu, J. ; Huang, F. Y.DKFZ* ; Leppä, A.-M. ; Wang, B. ; Abbas, H. A. ; Abkowitz, J. L. ; Appelbaum, J. S. ; Kaufmann, S. H. ; Becker, P. S. ; Trumpp, A.DKFZ* ; Jobanputra, V. ; Fang, M. ; Swisher, E. M. ; Doulatov, S.

2026
American Society of Hematology Washington, DC

Abstract: Clonal acquisition of multiple chromosomal abnormalities in hematopoietic stem and progenitor cells (HSPCs) is a hallmark of high-risk acute myeloid leukemias with complex karyotype (AML-CK). AML-CK is associated with TP53 mutations and chromosome 5q deletions (del5q); however, the drivers and clonal trajectories of aneuploid evolution in HSPCs remain unknown. We have developed a patient-derived induced pluripotent stem cell (iPSC) model in which preleukemic HSPCs clonally evolve to distinct, highly aneuploid states following transient mitotic inhibition. By tracking chromosome evolution at single cell resolution, we show that TP53-mutant HSPCs with del5q, but not TP53- mutation alone, evolved complex chromosomal changes. Clonal evolution was marked by stepwise acquisition of numerical and structural chromosome changes seen in AML-CK patients, with individual abnormalities conferring fitness advantage. iPSC-derived aneuploid HSPCs and primary AML-CK patient samples exhibited a conserved gene expression signature marked by upregulation of PTEN, cohesins, and anti-apoptotic factor BCL2, indicative of a shared aneuploid cell state in HSPCs. Clinical BCL2 inhibitor venetoclax eradicated BCL2-dependent aneuploid clones, with resistant clones undergoing a lineage switch to upregulate alternative BCL2 factors. In summary, we demonstrate that mutant TP53 and del5q drive chromosome evolution marked by stepwise acquisition of individual abnormalities. Moreover, aneuploid HSPCs exhibit a shared gene expression state which confers unique targetable therapeutic vulnerabilities in AML-CK.

Note: epub

---

Contributing Institute(s):

1. A010 Stammzellen und Krebs (A010)

Research Program(s):

1. 311 - Zellbiologie und Tumorbiologie (POF4-311) (POF4-311)

Appears in the scientific report 2026

---

Database coverage:
; ; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Current Contents - Life Sciences ; Ebsco Academic Search ; Essential Science Indicators ; IF >= 20 ; JCR ; PubMed Central ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---